Trial Profile
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms BRISK-PS
- Sponsors Bristol-Myers Squibb
- 27 Sep 2019 Status changed from discontinued to completed.
- 18 Sep 2018 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 17 Aug 2018 Status changed to discontinued as the efficacy endpoint met, however, overall experimental dosing regimen is not considered optimal to support further clinical development in this patient population